Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Find Successful Magnificence Items for Sparkling Skin - 2Civilian toll mounts in Iran as war presses on
- 3Photos: Presidential turkey pardons — a look back
- 4Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- 5‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Your kid wants it now. What saying yes, no or not yet teaches kids about money and instant gratification.
- 6 Objections for an Ocean side Wedding
- 5 Movies That Leaving an Imprint with Inventive Innovation
- Viable Correspondence: Building Solid Connections
- Ways to track down the Right Criminal Legal counselor
- Dozens injured in Russia after train crashes, overturns
- Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
- Governments take targeted action as fuel prices hit retail
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
